Certara (NASDAQ:CERT) Hits New 12-Month Low – Here’s What Happened

Certara, Inc. (NASDAQ:CERT)’s share price reached a new 52-week low on Wednesday . The company traded as low as $6.44 and last traded at $6.5880, with a volume of 172340 shares traded. The stock had previously closed at $6.51.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on CERT shares. Wall Street Zen downgraded shares of Certara from a “buy” rating to a “hold” rating in a report on Sunday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Certara in a report on Monday, December 29th. Morgan Stanley reduced their price target on Certara from $16.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, December 18th. Barclays decreased their price target on Certara from $14.00 to $13.00 and set an “overweight” rating on the stock in a research note on Monday, December 15th. Finally, KeyCorp cut their price objective on Certara from $13.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $12.82.

Certara Stock Performance

The company has a quick ratio of 2.09, a current ratio of 2.09 and a debt-to-equity ratio of 0.27. The stock has a fifty day moving average price of $8.71 and a two-hundred day moving average price of $10.09. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of 94.07 and a beta of 1.47.

Institutional Trading of Certara

Hedge funds and other institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC acquired a new stake in shares of Certara during the first quarter worth $259,000. Goldman Sachs Group Inc. lifted its position in Certara by 65.6% during the first quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock worth $2,267,000 after buying an additional 90,724 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Certara by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock worth $2,965,000 after buying an additional 35,954 shares during the last quarter. Jane Street Group LLC grew its holdings in Certara by 17.1% in the 1st quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock valued at $2,743,000 after buying an additional 40,463 shares during the period. Finally, Teacher Retirement System of Texas increased its stake in shares of Certara by 25.3% during the 2nd quarter. Teacher Retirement System of Texas now owns 5,674,485 shares of the company’s stock valued at $66,391,000 after acquiring an additional 1,145,554 shares during the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.